CannaPharmaRX (CPMD) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	13-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	CPMD
Entity Registrant Name	CANNAPHARMARX, INC.
Entity Central Index Key	1081938
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		18,444,075

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$1,385,003	$1,605,239
Prepaid expenses	40,351	44,102
Total current assets	1,425,354	1,649,341
Fixed Assets:
Furniture and fixtures, net of $6,155 in accumulated depreciation	96,644	97,701
Deposits on specialty pharmacy acquisition & prepaid financing costs	75,000	50,000
Total Assets	1,596,998	1,797,042
Current liabilities
Accounts payable and accrued expenses	201,130	137,772
Accrued legal settlement payable in cash - current portion	250,000	205,000
Accrued legal settlement payable in stock	1,597,500	1,597,500
Total current liabilities	2,048,630	1,940,272
Accrued legal settlement payable in cash - noncurrent portion	100,000	145,000
Total Liabilities	2,148,630	2,085,272
Stockholders' Equity
Preferred stock; $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 100,000,000 shares authorized; 17,677,407 and 17,374,407 issued and outstanding, respectively	1,768	1,737
Additional paid in capital	22,249,420	20,855,381
Retained deficit	-22,802,820	-21,145,348
Total Stockholders' Equity	-551,632	-288,230
Total Liabilities and Stockholders' Equity	$1,596,998	$1,797,042

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accumulated depreciation	$6,155	$6,155
Preferred stock, par value per share	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	17,677,407	17,374,407
Common stock, shares outstanding	17,677,407	17,374,407

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue	$0	$0
Operating Expenses:
Research and development	160,842
General and administrative	556,284	21,108
Stock-based compensation:
Stock-based compensation	939,569
Total operating expenses	1,656,695	21,108
Income (loss) from operations	-1,656,695	-21,108
Other income (expense)
Interest income (expense) net	-777	-4,530
Other income (expense) net	-777	-4,530
Income (loss) before provision for income taxes	-1,657,472	-25,638
Net loss	-1,657,472	-25,638
Net loss per share (Basic and fully diluted)	($0.09)	($0.01)
Weighted average number of common shares outstanding	17,475,407	2,384,407
Research and Development [Member]
Stock-based compensation:
Stock-based compensation	398,451
General and Administrative [Member]
Stock-based compensation:
Stock-based compensation	$541,118

Condensed_Statement_of_Stockho

Condensed Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Paid in Capital [Member]	Retained Deficit [Member]
Beginning Balance at Dec. 31, 2012	($197,628)	$238	$16,874,643	($17,072,509)
Beginning Balance, shares at Dec. 31, 2012		2,384,407
Net loss	-94,406			-94,406
Ending Balance at Dec. 31, 2013	-292,034	238	16,874,643	-17,166,915
Beginning Balance, shares at Dec. 31, 2013		2,384,407
CPRX acquisition	296,000	900	295,100
CPRX acquisition, shares		9,000,000
Debt relief in sale	71,672		71,672
Common stock sold	3,035,000	599	3,034,401
Common stock sold, shares		5,990,000
Stock-based compensation	579,565		579,565
Net loss	-3,978,433			-3,978,433
Ending Balance at Dec. 31, 2014	-288,230	1,737	20,855,381	-21,145,348
Ending Balance, shares at Dec. 31, 2014		17,374,407
Common stock sold	454,501	31	454,470
Common stock sold, shares		303,000
Stock-based compensation	939,569		939,569
Net loss	-1,657,472			-1,657,472
Ending Balance at Mar. 31, 2015	($551,632)	$1,768	$22,249,420	($22,802,820)
Ending Balance, shares at Mar. 31, 2015		17,677,407

Condensed_Statement_of_Cash_Fl

Condensed Statement of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash Flows From Operating Activities:
Net loss	($1,657,472)	($25,638)
Adjustments to reconcile net income to net cash provided by (used for) operating activities:
Depreciation expense	3,135	0
Stock-based compensation expense	939,569	0
Compensatory loan increases		15,000
Changes in operating assets & liabilities:
Decrease in prepaid expenses	3,751
Increase in accounts payable and accrued expenses	63,358	510
Increase in accrued interest payable - related party		4,081
Net cash used for operating activities	-647,659	-6,047
Cash Flows From Investing Activities:
Purchase of fixed assets	-2,078
Deposits paid toward specialty pharmacy acquisition & prepaid financing costs	-25,000
Net cash used for investing activities	-27,078
Cash Flows From Financing Activities:
Proceeds from (paydowns of) related party loans		6,047
Proceeds from sales of common stock	454,501
Net cash provided by financing activities	454,501	6,047
Net Increase (Decrease) In Cash	-220,236
Cash At The Beginning Of The Period	1,605,239
Cash At The End Of The Period	1,385,003
Schedule of Non-Cash Investing and Financing Activities
Related party loans		15,000
Supplemental Disclosure
Cash paid for interest	777
Cash paid for income taxes	$500

Nature_of_Operations_and_Signi

Nature of Operations and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Nature of Operations and Significant Accounting Policies	NOTE 1.	NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES
	NATURE OF OPERATIONS
	BUSINESS
	CannaPharmaRx, Inc. (together with its consolidated subsidiaries, the “Company”) is a Delaware corporation whose shares are publicly quoted on the OTCQB operated by the OTC Markets Group, Inc. The Company began trading under its new stock ticker symbol “CPMD,” effective as of March 21, 2015. We are an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development.
	HISTORY
	The Company was originally incorporated as Golden Dragon Holding Co. in the State of Delaware in December 2010 as a wholly-owned subsidiary of Concord Ventures, Inc. On May 9, 2014, the Company entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with CannaPharmaRX, Inc., a Colorado corporation (“CannaRx”), and David Cutler, the former President, Chief Executive Officer, Chief Financial Officer and director of the Company. Under the Share Purchase Agreement, CannaRx purchased 1,421,120 restricted shares of the Company’s common stock from Mr. Cutler and an additional 9,000,000 restricted shares of the Company’s common stock directly from the Company. As a result of the Share Purchase Agreement, CannaRx is the Company’s largest stockholder.
	On May 15, 2014, the Company entered into an Agreement and Plan of Merger (the “Plan of Merger”) pursuant to which CannaRx would become a subsidiary of the Company. In October 2014, the Company changed its legal name to CannaPharmaRx, Inc. During the fourth quarter of 2014, in light of the Cohen litigation described in Note 7 (Legal Proceedings), the parties determined to delay the closing of the transaction contemplated by the original Plan of Merger. On March 30, 2015, the parties to the Cohen litigation entered into a full settlement and release of claims agreement. With the Cohen litigation matter settled, on April 21, 2015, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) with CannaRx and CPHR Acquisition Corp., a Delaware Corporation and a wholly-owned subsidiary of the Company (“Acquisition Sub”), pursuant to which Acquisition Sub will merge with and into CannaRx with CannaRx remaining as the surviving corporation and wholly-owned subsidiary of the Company and the outstanding shares of CannaRx will be converted into 9,750,000 shares of the Company (the “Merger”). The Merger Agreement amends and restates in its entirety the Plan of Merger from May 2014. The Merger is subject to conditions to closing customary of transactions of this type, including, among others, CannaRx shareholder approval. The parties are proceeding to obtain approval of the Merger Agreement by the shareholders of CannaRx. Closing of the Merger is contemplated to occur in the second quarter of 2015, though no assurance can be given that this will occur. Upon the closing of the Merger, CannaRx will no longer be a stockholder of the Company, but the holders of CannaRx stock immediately prior to the Merger will become stockholders of the Company.
	BASIS OF PRESENTATION
	The accompanying unaudited interim financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States. Certain amounts in prior periods have been reclassified to conform to current presentation.
	Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ended December 31, 2015. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014 included in our Form 10-K filed with the SEC.
	USE OF ESTIMATES
	The preparation of our financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. Actual results could differ from those estimates. Due to uncertainties inherent in the estimation process, it is possible that these estimates could be materially revised within the next year.
	CASH AND CASH EQUIVALENTS
	Cash and cash equivalents consist of cash and highly liquid debt instruments with original maturities of less than three months.
	PROPERTY AND EQUIPMENT
	The Company has acquired $102,800 in property and equipment, of which $100,721 was purchased during the year ended December 31, 2014, and another $2,078 purchased in the first quarter of 2015. Of this amount, $50,000 represents the capitalized cost of our proprietary RECRUIT RegistryTM website development. This patient registry project was completed in the fourth quarter of 2014, although it will not become operational until mid-2015. Accordingly, no depreciation expense was recorded against the capitalized cost of the RECRUIT Registry to date.
	In addition to the investment in our patient registry, another $52,800 has been invested in office and computer equipment, primarily incurred since the establishment of the Company’s new headquarters in Carneys Point, New Jersey on November 1, 2014. Accumulated depreciation to date totaled $6,155 against this $52,800 of fixed assets actually placed in service. Depreciation expenses totaled $3,135 and $-0- in the quarters ended March 31, 2015 and March 31, 2014, respectively. Depreciation expense been calculated using the straight line method over the estimated useful lives of the respective assets, ranging from three to seven years.
	DEFERRED COSTS AND OTHER OFFERING COSTS
	Costs with respect to raising capital in the two private placements of the Company’s common stock were expensed by the Company both in 2014 and 2015. These costs were applied as internal operational expenses. We had no deferred costs and other stock offering costs as of either March 31, 2015 or December 31, 2014.
	However, the Company did incur accumulated costs totaling $25,000 in the quarter ended March 31, 2015 associated with the proposed financing of a specialty pharmacy acquisition, the terms of which are currently being negotiated. No assurance can be provided that an agreement to complete such acquisition will be entered into or that such acquisition will be consummated. These non-refundable fees for underwriting and due diligence on behalf of the lenders will be amortized over the life of the loans(s).
	Future costs associated with raising capital, be it debt or equity, may more likely be incurred as a direct variable cost with third parties. Our intent is to initially defer these costs and ultimately offset against the proceeds from these capital or financial transactions if successful, or expensed if the proposed financial transaction proves unsuccessful.
	IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS
	In the event that facts and circumstances indicated that the cost of long-lived and intangible assets may be impaired, an evaluation of recoverability will be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset will be compared to the asset’s carrying amount to determine if a write-down to market value or discounted cash flow value will be required.
	FAIR VALUES OF ASSETS AND LIABILITIES
	The Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.
			Level 1:	Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.
			Level 2:	Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.
			Level 3:	Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.
	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. As of March 31, 2015 and December 31, 2014, the Company does not have any assets or liabilities which are considered Level 2 or 3 in the hierarchy.
	The Company may also be required, from time to time, to measure certain other financial assets at fair value on a nonrecurring basis. These adjustments to fair value usually result from application of lower-of-cost-or-market accounting or write-downs of individual assets. There were no such adjustments in the periods ended March 31, 2015, nor December 31, 2014.
	FINANCIAL INSTRUMENTS
	The estimated fair value for financial instruments was determined at discrete points in time based on relevant market information. These estimates involved uncertainties and could not be determined with exact precision. The fair value of the Company’s financial instruments, which include cash, prepaid expenses, accounts payable and the related party loan, each approximate their carrying value due either to their short length to maturity or interest rates that approximate prevailing market rates.
	INCOME TAXES
	We account for income taxes under the liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
	ADVERTISING COSTS
	Advertising and promotional costs are expensed as incurred. Advertising and promotional expenses totaled $1,157 in the quarter ended March 31, 2015 and $-0- for the quarter ended March 31, 2014.
	COMPREHENSIVE INCOME (LOSS)
	Comprehensive income is defined as all changes in stockholders’ equity (deficit), exclusive of transactions with owners, such as capital investments. Comprehensive income includes net income or loss, changes in certain assets and liabilities that are reported directly in equity such as translation adjustments on investments in foreign subsidiaries and unrealized gains (losses) on available-for-sale securities. From our inception, there have been no differences between our comprehensive loss and net loss. Our comprehensive loss was identical to our net loss for the three months ended March 31, 2015 and 2014.
	INCOME (LOSS) PER SHARE
	Income (loss) per share is presented in accordance with Accounting Standards Update (“ASU”), Earning per Share (Topic 260) which requires the presentation of both basic and diluted earnings per share (“EPS”) on the consolidated income statements. Basic EPS would exclude any dilutive effects of options, warrants and convertible securities but does include the restricted shares of common stock issued. Diluted EPS reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Basic EPS calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted EPS calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.
	Stock options outstanding at March 31, 2015 to purchase 4,275,000 shares of common stock are excluded from the calculations of diluted net loss per share since their effect is antidilutive.
	STOCK-BASED COMPENSATION
	We have adopted ASC Topic 718, Accounting for Stock-Based Compensation, which establishes a fair value method of accounting for stock-based compensation plans. In accordance with guidance now incorporated in ASC Topic 718, the cost of stock options and warrants issued to employees and non-employees is measured on the grant date based on the fair value. The fair value is determined using the Black-Scholes option pricing model. The resulting amount is charged to expense on the straight-line basis over the period in which we expect to receive the benefit, which is generally the vesting period. The fair value of stock warrants was determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option model requires management to make various estimates and assumptions, including expected term, expected volatility, risk-free rate and dividend yield.
	On November 1, 2014, the Company granted options to purchase shares of the Company’s common stock to each of its employees for a total of 4,800,000 options granted. Including the November 1, 2014 grant and all subsequent option grants, the Company has granted a total of 5,475,000 options. As a result of forfeitures, 4,275,000 options remain outstanding as of March 31, 2015. Stock-based compensation expenses totaled $939,569 and $-0- for the three months ended March 31, 2015 and March 31, 2014.
	BUSINESS SEGMENTS
	Our activities during the three months ended March 31, 2015 comprised a single segment.
	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	On June 10, 2014, the FASB issued update ASU 2014-10, Development Stage Entities (Topic 915). Amongst other things, the amendments in this update removed the definition of development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and stockholders’ equity, (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments are effective for annual reporting periods beginning after December 31, 2014 and interim reporting periods beginning after December 15, 2015. However, entities are permitted to early adopt for any annual or interim reporting period for which the financial statements have yet to be issued. The Company has elected to early adopt these amendments, and accordingly, has not labeled the financial statements as those of a development stage entity and has not presented inception-to-date information on the respective financial statements.
	We have reviewed all other recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of our operations.

Going_Concern_and_Liquidity

Going Concern and Liquidity	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Going Concern and Liquidity	NOTE 2.	GOING CONCERN AND LIQUIDITY
	The Company had cash on hand of $1,385,003 as of March 31, 2015, but no revenue-producing business or other sources of income. Additionally, the Company had outstanding liabilities totaling $2,148,630 (of which $1,597,500 subsequently was settled in May 2015 with the issuance of common stock) and a stockholders’ deficit of $551,632.
	We had a working capital deficit of $623,276 at March 31, 2015 (which includes an offset of $1,597,500 in current liabilities that subsequently was settled in stock in May 2015) and reported an accumulated deficit since inception (January 1, 2011) of $551,632 as of March 31, 2015.
	In our financial statements for the fiscal years ended December 31, 2014 and 2013, the Report of the Independent Registered Public Accounting Firm includes an explanatory paragraph that describes substantial doubt about our ability to continue as a going concern. These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. It is our current intention to raise debt and/or equity financing to fund ongoing operating expenses. There is no assurance that these events will be satisfactorily completed or at terms acceptable to the Company. Any issuance of equity securities, if accomplished, could cause substantial dilution to existing stockholders.

Assets

Assets	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Assets	NOTE 3.	ASSETS
	As of March 31, 2015, we had $1,425,354 in current assets, primarily comprised of: $1,385,003 in cash on deposit in a bank and $40,351 in prepaid insurance, $96,644 in furniture and fixtures, net of $6,155 in accumulated depreciation, and $75,000 on deposit related to the proposed acquisition of a specialty pharmacy and prepaid financing fees associated with this acquisition, the terms of which are currently being negotiated. No assurance can be provided that an agreement to complete such acquisition will be entered into or that such acquisition will be consummated.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 4.	ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	As of March 31, 2015, the balance of accounts payable and accrued expenses was $201,130, which is primarily comprised of trade payables and accrued salaries and wages and legal fees.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 5.	COMMITMENTS
	OPERATING LEASE
	The Company has a non-cancellable operating lease for its headquarters located in Carneys Point, New Jersey. The term of this lease extends until October 31, 2015. The remaining lease commitment totals $25,879 as of March 31, 2015.

Litigation_and_Accrued_Settlem

Litigation and Accrued Settlement Liabilities	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Litigation and Accrued Settlement Liabilities	NOTE 6.	LITIGATION AND ACCRUED SETTLEMENT LIABILITIES
	On October 30, 2014, Gary M. Cohen (“Cohen”), former President, Chief Operating Officer and board member of CannaRx, a privately-held Colorado corporation, filed a lawsuit against CannaRx and individual officer and board member, Gary Herick. On November 26, 2014, Cohen filed an amended complaint naming the Company and Gerald Crocker, James Smeeding, Robert Liess and Mathew Sherwood. In his amended complaint, Cohen alleged various employment-related contract and wrongful termination claims, as well as claims alleging breach of fiduciary duty, misappropriation of assets, violations of corporate law regarding his access to internal corporate information, and alleged violations of U.S. federal securities laws, the Sarbanes-Oxley Act of 2002 and the U.S. Internal Revenue Code. Cohen’s claims arose out of the removal of Cohen as an officer and board member of CannaRx, which occurred on or about October 23, 2014. The defendants successfully removed Cohen’s lawsuit from state court in Hillsborough County, Florida—where it was filed originally—to the U.S. District Court in Tampa, Florida.
	On November 11, 2014, the Company, under its former name Golden Dragon Holding Co. (“GDHC”), sued Cohen in U.S. District Court in New Jersey for libel and tortious interference.
	On March 30, 2015, the Company executed a Confidential Settlement and Release of Claims Agreement dated March 30, 2015 by and between the Company, CannaRx, Cohen and the other individuals named above (the “Settlement Agreement”). Pursuant to the terms of the Settlement Agreement, the lawsuit filed in Florida on October 30, 2014 against the Company, Canna Colorado, Herick, Crocker, Smeeding, Sherwood and Liess by Cohen has been resolved and dismissed. The parties amicably resolved their differences before any discovery occurred or before any decision by the court on the merits of any claims. The Company and all the individuals who had been sued categorically denied of all Mr. Cohen’s claims and allegations, maintained that the allegations were false and were prepared to assert counterclaims of their own. As part of the parties’ resolution, Cohen has agreed to retract his allegations.
	As part of the Settlement Agreement, the Company agreed to purchase all of Mr. Cohen’s 2,250,000 shares of CannaRx for a purchase price of $350,000, with $85,000 payable up front and the remainder payable in equal installments of $15,000 per month over the next 17 months, and a payment of $10,000 in the eighteenth month. The amount of cash payable in the next year of $250,000 is included in current liabilities. In addition, the Company agreed to issue 600,000 unregistered restricted shares of its common stock to Mr. Cohen as part of the Settlement Agreement. The Company valued those shares at $1,597,500 based on the trading average of the Company’s stock over the ten days preceding entry into the Settlement Agreement and recorded an expense in such amount during the period ended December 31, 2014. The liability associated with the obligation to deliver 600,000 shares is reflected in current liabilities as of both March 31, 2015 and December 31, 2014. These shares subsequently were issued by the Company to Mr. Cohen on May 4, 2015 in full settlement of the stock portion of liability and $100,000 has been paid to Mr. Cohen in cash through May 12, 2015 in accordance with the settlement payment terms, leaving a remaining liability of $250,000 as of May 12, 2015 to be paid in cash in the future.
	In addition, the Company and Cohen have resolved their differences in the Company’s lawsuit filed against Cohen on November 11, 2014 in New Jersey. The Company has dismissed its claims against Cohen of libel and tortious interference.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	NOTE 7.	STOCKHOLDERS’ EQUITY
	PREFERRED STOCK
	The Company is authorized, without further action by the shareholders, to issue up to 10,000,000 shares of one or more series of preferred stock, at a par value of $0.0001, all of which is nonvoting. The Board of Directors may, without shareholder approval, determine the dividend rates, redemption prices, preferences on liquidation or dissolution, conversion rights, voting rights and any other preferences. No shares of preferred stock were issued or outstanding as of March 31, 2015.
	COMMON STOCK
	The Company is authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share. As of March 31, 2015, 17,677,407 shares of common stock were issued and outstanding and an additional 9,750,000 shares of common stock are reserved for issuance pursuant to the Merger Agreement.
	RECENT ISSUANCES OF COMMON STOCK
	In March 2015, the Company began offering in a private placement of shares of its unregistered restricted common stock to accredited investors at $1.50 per share (the “Private Placement”). Two closings have occurred under the Private Placement. Through March 31, 2015 the Company issued a total of 303,001 shares in exchange for $454,501 of anticipated gross proceeds. On April 23, 2015, an additional 166,667 shares were issued for a total of $250,000 in gross proceeds, resulting in an aggregate total of 469,668 shares to date in the offering and $704,501 in gross proceeds.
	WARRANTS
	On January 20, 2015, the Company issued a 3-year warrant (the “First Warrant”) to Viridian Capital & Research, LLC (“VCR”) as compensation for the services rendered by VCR in connection with the delivery of a company report describing the business, technology and products, markets, growth strategy and financial aspects of the Company. The First Warrant is exercisable into 244,283 of the Company’s fully-diluted common shares at an exercise price equal to the price per share of the Company’s common stock on the 10 days preceding January 20, 2015 or $2.90. The First Warrant has a 3-year life, a cashless exercise provision and is fully transferable with the Company’s approval, which shall not be unreasonably withheld. The First Warrant is callable on 60 days’ notice if (i) the Company’s common stock trades on the NASDAQ and (ii) the Company’s common stock trades at three times the exercise price of the First Warrant for 20 consecutive trading days.
	On February 23, 2015, the Company issued another 3-year warrant (the “Second Warrant,” and together with the First Warrant, the “VCR Warrants”) to VCR as compensation for VCR’s services in managing and implementing investor relations strategies designed to enhance the Company’s presence, reach and mindshare with the U.S. investment community and industry. The Second Warrant is exercisable into 244,283 of the Company’s fully-diluted common shares at an exercise price equal to the price per share of the Company’s common stock on the 10 days preceding February 23, 2015 or $2.50. The Second Warrant has a 3-year life, a cashless exercise provision and is fully transferable with the Company’s approval, which shall not be unreasonably withheld. The Second Warrant is callable on 60 days’ notice if (i) the Company’s common stock trades on the NASDAQ and (ii) the Company’s common stock trades at three times the exercise price of the Second Warrant for 20 consecutive trading days.
	STOCK OPTIONS
	To date, the following stock options were issued and outstanding to employees, which were not issued pursuant to a formal equity compensation plan:
			For the Three Months Ended
			March 31, 2015
			Shares		Option		Weighted
					Price		Average
							Price
	Outstanding Options at Beginning of Period			3,600,000	$	3.78	$	3.78
	Options Granted			675,000	$	3	$	3
	Options Forfeited			—		—		—
	Options Outstanding at End of Period			4,275,000	$	3.66	$	3.66
	Options Exercisable at End of Period			—
	Effective November 1, 2014, the Company issued options to purchase 4,800,000 shares at an exercise price of $3.78 per share. During the first quarter of 2015, the Company issued additional options to purchase 675,000 shares to newly hired employees at an average weighted exercise price of $3.00 per share. The exercise price was determined based on the closing stock price quoted on the day prior to their issuance. The options vest over a three year period from the date of issuance, one-third at each anniversary date.
	As a result of the 2014 and 2015 stock option activity to date, the Company has recorded aggregate stock-based compensation charges of $939,569 in the quarter ended March 31, 2015.
	Stock-based compensation charges remaining to be amortized total $10,467,212 at March 31, 2015. These remaining stock-based compensation charges will be amortized to expense over the remaining vesting period through March 2018 in accordance with their vesting schedules.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8.	INCOME TAXES
	We have had losses since our inception (January 1, 2011) and therefore have not been subject to federal or state income taxes since our inception. As of March 31, 2015, the Company has approximately $2,464,000 and $2,256,000 of federal and state net operating loss carryforwards, respectively. The federal net operating loss carryforwards begin to expire in 2030 and the state net operating loss carryforwards begin to expire in 2034.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 9.	SUBSEQUENT EVENTS
	We have evaluated subsequent events through the date of this filing and note there have been no events that would require disclosure in this report, other than (i) the entry into the Amended and Restated Merger Agreement discussed in Note 1 above, (ii) the litigation settlement agreement between the Company and Mr. Cohen discussed in Note 6 above and (iii) the April 2015 issuance of common stock as a result of the private placement started in March 2015 discussed in Note 7 above.

Nature_of_Operations_and_Signi1

Nature of Operations and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONS
	BUSINESS
	CannaPharmaRx, Inc. (together with its consolidated subsidiaries, the “Company”) is a Delaware corporation whose shares are publicly quoted on the OTCQB operated by the OTC Markets Group, Inc. The Company began trading under its new stock ticker symbol “CPMD,” effective as of March 21, 2015. We are an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development.
	HISTORY
	The Company was originally incorporated as Golden Dragon Holding Co. in the State of Delaware in December 2010 as a wholly-owned subsidiary of Concord Ventures, Inc. On May 9, 2014, the Company entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with CannaPharmaRX, Inc., a Colorado corporation (“CannaRx”), and David Cutler, the former President, Chief Executive Officer, Chief Financial Officer and director of the Company. Under the Share Purchase Agreement, CannaRx purchased 1,421,120 restricted shares of the Company’s common stock from Mr. Cutler and an additional 9,000,000 restricted shares of the Company’s common stock directly from the Company. As a result of the Share Purchase Agreement, CannaRx is the Company’s largest stockholder.
	On May 15, 2014, the Company entered into an Agreement and Plan of Merger (the “Plan of Merger”) pursuant to which CannaRx would become a subsidiary of the Company. In October 2014, the Company changed its legal name to CannaPharmaRx, Inc. During the fourth quarter of 2014, in light of the Cohen litigation described in Note 7 (Legal Proceedings), the parties determined to delay the closing of the transaction contemplated by the original Plan of Merger. On March 30, 2015, the parties to the Cohen litigation entered into a full settlement and release of claims agreement. With the Cohen litigation matter settled, on April 21, 2015, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) with CannaRx and CPHR Acquisition Corp., a Delaware Corporation and a wholly-owned subsidiary of the Company (“Acquisition Sub”), pursuant to which Acquisition Sub will merge with and into CannaRx with CannaRx remaining as the surviving corporation and wholly-owned subsidiary of the Company and the outstanding shares of CannaRx will be converted into 9,750,000 shares of the Company (the “Merger”). The Merger Agreement amends and restates in its entirety the Plan of Merger from May 2014. The Merger is subject to conditions to closing customary of transactions of this type, including, among others, CannaRx shareholder approval. The parties are proceeding to obtain approval of the Merger Agreement by the shareholders of CannaRx. Closing of the Merger is contemplated to occur in the second quarter of 2015, though no assurance can be given that this will occur. Upon the closing of the Merger, CannaRx will no longer be a stockholder of the Company, but the holders of CannaRx stock immediately prior to the Merger will become stockholders of the Company.
BASIS OF PRESENTATION	BASIS OF PRESENTATION
	The accompanying unaudited interim financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States. Certain amounts in prior periods have been reclassified to conform to current presentation.
	Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ended December 31, 2015. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014 included in our Form 10-K filed with the SEC.
USE OF ESTIMATES	USE OF ESTIMATES
	The preparation of our financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. Actual results could differ from those estimates. Due to uncertainties inherent in the estimation process, it is possible that these estimates could be materially revised within the next year.
CASH AND CASH EQUIVALENTS	CASH AND CASH EQUIVALENTS
	Cash and cash equivalents consist of cash and highly liquid debt instruments with original maturities of less than three months.
PROPERTY AND EQUIPMENT	PROPERTY AND EQUIPMENT
	The Company has acquired $102,800 in property and equipment, of which $100,721 was purchased during the year ended December 31, 2014, and another $2,078 purchased in the first quarter of 2015. Of this amount, $50,000 represents the capitalized cost of our proprietary RECRUIT RegistryTM website development. This patient registry project was completed in the fourth quarter of 2014, although it will not become operational until mid-2015. Accordingly, no depreciation expense was recorded against the capitalized cost of the RECRUIT Registry to date.
	In addition to the investment in our patient registry, another $52,800 has been invested in office and computer equipment, primarily incurred since the establishment of the Company’s new headquarters in Carneys Point, New Jersey on November 1, 2014. Accumulated depreciation to date totaled $6,155 against this $52,800 of fixed assets actually placed in service. Depreciation expenses totaled $3,135 and $-0- in the quarters ended March 31, 2015 and March 31, 2014, respectively. Depreciation expense been calculated using the straight line method over the estimated useful lives of the respective assets, ranging from three to seven years.
DEFERRED COSTS AND OTHER OFFERING COSTS	DEFERRED COSTS AND OTHER OFFERING COSTS
	Costs with respect to raising capital in the two private placements of the Company’s common stock were expensed by the Company both in 2014 and 2015. These costs were applied as internal operational expenses. We had no deferred costs and other stock offering costs as of either March 31, 2015 or December 31, 2014.
	However, the Company did incur accumulated costs totaling $25,000 in the quarter ended March 31, 2015 associated with the proposed financing of a specialty pharmacy acquisition, the terms of which are currently being negotiated. No assurance can be provided that an agreement to complete such acquisition will be entered into or that such acquisition will be consummated. These non-refundable fees for underwriting and due diligence on behalf of the lenders will be amortized over the life of the loans(s).
	Future costs associated with raising capital, be it debt or equity, may more likely be incurred as a direct variable cost with third parties. Our intent is to initially defer these costs and ultimately offset against the proceeds from these capital or financial transactions if successful, or expensed if the proposed financial transaction proves unsuccessful.
IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS	IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS
	In the event that facts and circumstances indicated that the cost of long-lived and intangible assets may be impaired, an evaluation of recoverability will be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset will be compared to the asset’s carrying amount to determine if a write-down to market value or discounted cash flow value will be required.
FAIR VALUES OF ASSETS AND LIABILITIES	FAIR VALUES OF ASSETS AND LIABILITIES
	The Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.
		Level 1:	Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.
		Level 2:	Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.
		Level 3:	Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.
	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. As of March 31, 2015 and December 31, 2014, the Company does not have any assets or liabilities which are considered Level 2 or 3 in the hierarchy.
	The Company may also be required, from time to time, to measure certain other financial assets at fair value on a nonrecurring basis. These adjustments to fair value usually result from application of lower-of-cost-or-market accounting or write-downs of individual assets. There were no such adjustments in the periods ended March 31, 2015, nor December 31, 2014.
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS
	The estimated fair value for financial instruments was determined at discrete points in time based on relevant market information. These estimates involved uncertainties and could not be determined with exact precision. The fair value of the Company’s financial instruments, which include cash, prepaid expenses, accounts payable and the related party loan, each approximate their carrying value due either to their short length to maturity or interest rates that approximate prevailing market rates.
INCOME TAXES	INCOME TAXES
	We account for income taxes under the liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
ADVERTISING COSTS	ADVERTISING COSTS
	Advertising and promotional costs are expensed as incurred. Advertising and promotional expenses totaled $1,157 in the quarter ended March 31, 2015 and $-0- for the quarter ended March 31, 2014.
COMPREHENSIVE INCOME (LOSS)	COMPREHENSIVE INCOME (LOSS)
	Comprehensive income is defined as all changes in stockholders’ equity (deficit), exclusive of transactions with owners, such as capital investments. Comprehensive income includes net income or loss, changes in certain assets and liabilities that are reported directly in equity such as translation adjustments on investments in foreign subsidiaries and unrealized gains (losses) on available-for-sale securities. From our inception, there have been no differences between our comprehensive loss and net loss. Our comprehensive loss was identical to our net loss for the three months ended March 31, 2015 and 2014.
INCOME (LOSS) PER SHARE	INCOME (LOSS) PER SHARE
	Income (loss) per share is presented in accordance with Accounting Standards Update (“ASU”), Earning per Share (Topic 260) which requires the presentation of both basic and diluted earnings per share (“EPS”) on the consolidated income statements. Basic EPS would exclude any dilutive effects of options, warrants and convertible securities but does include the restricted shares of common stock issued. Diluted EPS reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Basic EPS calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted EPS calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.
	Stock options outstanding at March 31, 2015 to purchase 4,275,000 shares of common stock are excluded from the calculations of diluted net loss per share since their effect is antidilutive.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION
	We have adopted ASC Topic 718, Accounting for Stock-Based Compensation, which establishes a fair value method of accounting for stock-based compensation plans. In accordance with guidance now incorporated in ASC Topic 718, the cost of stock options and warrants issued to employees and non-employees is measured on the grant date based on the fair value. The fair value is determined using the Black-Scholes option pricing model. The resulting amount is charged to expense on the straight-line basis over the period in which we expect to receive the benefit, which is generally the vesting period. The fair value of stock warrants was determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option model requires management to make various estimates and assumptions, including expected term, expected volatility, risk-free rate and dividend yield.
	On November 1, 2014, the Company granted options to purchase shares of the Company’s common stock to each of its employees for a total of 4,800,000 options granted. Including the November 1, 2014 grant and all subsequent option grants, the Company has granted a total of 5,475,000 options. As a result of forfeitures, 4,275,000 options remain outstanding as of March 31, 2015. Stock-based compensation expenses totaled $939,569 and $-0- for the three months ended March 31, 2015 and March 31, 2014.
BUSINESS SEGMENTS	BUSINESS SEGMENTS
	Our activities during the three months ended March 31, 2015 comprised a single segment.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	On June 10, 2014, the FASB issued update ASU 2014-10, Development Stage Entities (Topic 915). Amongst other things, the amendments in this update removed the definition of development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and stockholders’ equity, (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments are effective for annual reporting periods beginning after December 31, 2014 and interim reporting periods beginning after December 15, 2015. However, entities are permitted to early adopt for any annual or interim reporting period for which the financial statements have yet to be issued. The Company has elected to early adopt these amendments, and accordingly, has not labeled the financial statements as those of a development stage entity and has not presented inception-to-date information on the respective financial statements.
	We have reviewed all other recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of our operations.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Stock Options	To date, the following stock options were issued and outstanding to employees, which were not issued pursuant to a formal equity compensation plan:
		For the Three Months Ended
		March 31, 2015
		Shares		Option		Weighted
				Price		Average
						Price
	Outstanding Options at Beginning of Period		3,600,000	$	3.78	$	3.78
	Options Granted		675,000	$	3	$	3
	Options Forfeited		—		—		—
	Options Outstanding at End of Period		4,275,000	$	3.66	$	3.66
	Options Exercisable at End of Period		—

Nature_of_Operations_and_Signi2

Nature of Operations and Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended			5 Months Ended	12 Months Ended	15 Months Ended
	Nov. 01, 2014	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Apr. 21, 2015	9-May-14
		Private_placement		Private_placement
		Segment
Nature Of Operations [Line Items]
Shares issuable upon merger		9,750,000			9,750,000		9,750,000
Property and equipment acquired		$2,078				$100,721	$102,800
Website development for cannabinoid medicines			50,000
Depreciation expense recorded against capitalized cost							0
Payments to acquire office and computer equipment		52,800
Accumulated depreciation		6,155	6,155		6,155	6,155	6,155
Depreciation expense		3,135		0
Number of private placements		2		2
Deferred cost and other offering costs		0	0		0	0	0
Deferred costs associated with proposed financing		25,000			25,000		25,000
Advertising and promotional expenses		1,157		0
Stock options excluded from calculation of diluted net income per share due to anti-dilutive effect (in shares)		4,275,000
Options issued during period	4,800,000				5,475,000
Options outstanding		4,275,000	3,600,000		4,275,000	3,600,000	4,275,000
Stock-based compensation expense		$939,569		$0
Number of reportable segment		1
Subsequent Event [Member] | Canna Pharma RX [Member]
Nature Of Operations [Line Items]
Shares issuable upon merger								9,750,000
Minimum [Member]
Nature Of Operations [Line Items]
Estimated useful lives of assets		3 years
Maximum [Member]
Nature Of Operations [Line Items]
Estimated useful lives of assets		7 years
Share Purchase Agreement [Member]
Nature Of Operations [Line Items]
Number of shares repurchased									1,421,120
Number additional shares repurchased									9,000,000

Going_Concern_and_Liquidity_Ad

Going Concern and Liquidity - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Going Concern And Liquidity [Abstract]
Cash	$1,385,003	$1,605,239
Liabilities	2,148,630	2,085,272
Stockholders' equity (deficit)	-551,632	-288,230	-292,034	-197,628
Settlement payable in stock - current liabilities	1,597,500	1,597,500
Working capital (deficit)	($623,276)

Assets_Additional_Information_

Assets - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Assets [Abstract]
Current assets	$1,425,354	$1,649,341
Cash and cash equivalents	1,385,003	1,605,239
Prepaid expenses	40,351	44,102
Furniture and fixtures, net of accumulated depreciation	96,644	97,701
Furniture and fixtures, accumulated depreciation	6,155	6,155
Deposit on specialty pharmacy acquisition	$75,000

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses - Additional Information (Detail) (USD $)	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$201,130

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Remaining lease commitment	$25,879
Non-cancellable operating lease expiration date	31-Oct-15

Litigation_and_Accrued_Settlem1

Litigation and Accrued Settlement Liabilities - Additional Information (Detail) (USD $)	3 Months Ended	1 Months Ended
	Mar. 31, 2015	12-May-15	Dec. 31, 2014	Mar. 30, 2015
Litigation And Other Contingencies [Line Items]
Legal settlement payable in cash - current liabilities	250,000		$205,000
Legal settlement payable in stock	1,597,500		1,597,500
Gary M. Cohen [Member]
Litigation And Other Contingencies [Line Items]
Settlement agreement, description	As part of the Settlement Agreement, the Company agreed to purchase all of Mr. Cohenbs 2,250,000 shares of CannaRx for a purchase price of $350,000, with $85,000 payable up front and the remainder payable in equal installments of $15,000 per month over the next 17 months, and a payment of $10,000 in the eighteenth month. The amount of cash payable in the next year of $250,000 is included in current liabilities. In addition, the Company agreed to issue 600,000 unregistered restricted shares of its common stock to Mr. Cohen as part of the Settlement Agreement.
Settlement agreement, share purchased				2,250,000
Settlement agreement, share purchase price				350,000
Settlement agreement, up front payment				85,000
Settlement amount payable in Equal Monthly installment up to seventeen month				15,000
Settlement amount final payment on eighteenth month				10,000
Unregistered restricted shares of common stock granted				600,000
Legal settlement payable in cash - current liabilities				250,000
Legal settlement payable in stock				1,597,500
Gary M. Cohen [Member] | Subsequent Event [Member]
Litigation And Other Contingencies [Line Items]
Legal settlement payable in cash - current liabilities		250,000
Cash paid in accordance with settlement payment terms		$100,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended	0 Months Ended			2 Months Ended
	Nov. 01, 2014	Mar. 31, 2015	Mar. 31, 2015	Jan. 20, 2015	Feb. 23, 2015	Apr. 23, 2015	Apr. 23, 2015	Dec. 31, 2014
			Private_placement
Class of Stock [Line Items]
Preferred stock, shares authorized		10,000,000	10,000,000					10,000,000
Preferred stock, par value per share		$0.00	$0.00					$0.00
Preferred stock, shares issued		0	0					0
Preferred stock, shares outstanding		0	0					0
Common stock, shares authorized		100,000,000	100,000,000					100,000,000
Common stock, par value per share		$0.00	$0.00					$0.00
Common stock, shares issued		17,677,407	17,677,407					17,374,407
Common stock, shares outstanding		17,677,407	17,677,407					17,374,407
Common stock reserved for issuance pursuant to merger agreement		9,750,000	9,750,000
Number of private placement closings			2
Unregistered restricted Common Stock, anticipated gross proceeds		$454,501
Options issued to purchase shares	4,800,000		675,000
Options exercise price per share	$3.78		$3
Stock options, vesting period			3 years
Stock-based compensation charges			939,569
Unamortized Stock based compensation charges		10,467,212	10,467,212
Unamortized Stock based compensation charges, end date of amortization period based on vesting period			2018-03
Viridian Capital and Research, LLC [Member] | First Warrant [Member]
Class of Stock [Line Items]
Warrant expiration term				3 years
Number of Securities exercised by Warrants or Rights				244,283
Exercise Price of Warrants per warrant				$2.90
Exercise Price of Warrants, description			Price per share of the Company's common stock on the 10 days preceding January 20, 2015 or $2.90
Notice period to call warrants				60 days
Warrants callable description			The First Warrant is callable on 60 days' notice if (i) the Company's common stock trades on the NASDAQ and (ii) the Company's common stock trades at three times the exercise price of the First Warrant for 20 consecutive trading days
Number of trading days to trade company's common stock				20 days
Viridian Capital and Research, LLC [Member] | Second Warrant [Member]
Class of Stock [Line Items]
Warrant expiration term					3 years
Number of Securities exercised by Warrants or Rights					244,283
Exercise Price of Warrants per warrant					$2.50
Exercise Price of Warrants, description			Price per share of the Company's common stock on the 10 days preceding February 23, 2015 or $2.50
Notice period to call warrants					60 days
Warrants callable description			The Second Warrant is callable on 60 days' notice if (i) the Company's common stock trades on the NASDAQ and (ii) the Company's common stock trades at three times the exercise price of the Second Warrant for 20 consecutive trading days
Number of trading days to trade company's common stock					20 days
Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Options vesting, percentage on each anniversary date			33.33%
Private Placement [Member]
Class of Stock [Line Items]
Unregistered restricted Common Stock, price per share		$1.50	$1.50
Unregistered restricted Common Stock, shares issued		303,001
Subsequent Event [Member]
Class of Stock [Line Items]
Unregistered restricted Common Stock, anticipated gross proceeds						$250,000	$704,501
Subsequent Event [Member] | Private Placement [Member]
Class of Stock [Line Items]
Unregistered restricted Common Stock, shares issued						166,667	469,668
Maximum [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		10,000,000	10,000,000

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Options (Detail) (USD $)	0 Months Ended	3 Months Ended
	Nov. 01, 2014	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding Options at Beginning of Period, Shares		3,600,000
Options Granted, Shares	4,800,000	675,000
Options Forfeited, Shares		0
Options Outstanding at End of Period, Shares		4,275,000
Options Exercisable at End of Period, Shares		0
Options Outstanding at Beginning of Period, Option Price		$3.78
Options Granted, Option Price	$3.78	$3
Options Forfeited, Option Price		$0
Options Outstanding at End of Period, Option Price		$3.66
Options Outstanding at Beginning of Period , Weighted Average Price		$3.78
Options Granted, Weighted Average Price		$3
Options Forfeited, Weighted Average Price		$0
Options Outstanding at End of Period, Weighted Average Price		$3.66

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$2,464,000
Net operating loss carryforward expiration year	2030
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$2,256,000
Net operating loss carryforward expiration year	2034